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The zinc finger structure that is found in the nucleocapsid protein of nearly all retroviruses has been proposed as a target
for antiviral therapy. Since compounds that chemically attack the cysteines of the finger have been shown to inactivate both
human immunodeficiency virus type 1 (HIV-1) and murine leukemia virus (MuLV) in vitro, 14 of these compounds were tested
in an MuLV-induced Friend disease model to assess their ability to inhibit retroviral replication in vivo. Of the 14 compounds
tested, only Aldrithiol-2 clearly exhibited anti-retroviral activity as measured indirectly by the delay of Friend disease onset
(P , 0.05). These results were confirmed by quantitative competitive polymerase chain reaction studies which monitored
viral spread by measuring the level of viral DNA in the peripheral blood mononuclear cells of treated mice. Comparison of
treated mice with untreated mice revealed that Aldrithiol-2 produced a greater than 2-log reduction in virus levels. These
results functionally demonstrate that a zinc finger-attacking compound can inhibit viral replication in vivo. Since only 1 of the
14 compounds studied was effective, this study also shows the importance of in vivo testing of these types of antiviral
compounds in an animal model. Given the strict conservation of the metal-coordinating cysteine structure within HIV-1 and
MuLV zinc fingers, our results support the proposal that anti-retroviral drugs which target the nucleocapsid zinc finger may
be clinically useful against HIV-1.
INTRODUCTION
The search for therapies against the human immuno-
deficiency virus type 1 (HIV-1) has produced two catego-
ries of clinical drugs that act upon either reverse tran-
scriptase or the viral protease (Hirsch and D’Aquila,
1993; Levy, 1995; Roberts et al., 1990). While therapies
against either of these enzymes have proven to be ini-
tially effective, HIV-1 can develop resistance over time to
treatments that employ only one of these compounds
(Condra et al., 1995; Holodniy et al., 1995; Richman, 1995;
Richman et al., 1994). Given these results, successful
current and future drug therapies use and will likely use
a combination of several drugs, each acting on a differ-
ent viral target, to decrease the likelihood of selecting a
resistant mutant to any one single compound in the
multiple drug treatment (Coffin, 1995; Gulick et al., 1997;
Hammer et al., 1997). Therefore, it is important to con-
sider and exploit additional retroviral targets other than
the reverse transcriptase or protease enzymes for anti-
viral compounds.
The retroviral zinc finger found in HIV-1 nucleocapsid
protein has been proposed as a target for drug therapy
(Gorelick et al., 1990, 1997; Rice et al., 1993, 1995b). This
structure consists of three cysteines and a histidine in a
Cys-(X)2-Cys-(X)4-His-(X)4-Cys (CCHC) configuration that
coordinates a Zn21 ion and forms a finger-like structure
(Chance et al., 1992; Green and Berg, 1989; Summers et
al., 1993). The retroviral nucleocapsid CCHC zinc finger
structure is also strictly conserved, encoded in either
one or two copies within all gag genes except those of
the spumaviruses (Maurer et al., 1988). Studies with
deletional and site-directed mutations in the nucleocap-
sid protein of avian, murine, and HIV-1 viruses have
demonstrated that an intact zinc finger or fingers are
required for efficient packaging of genomic RNAs into
the virion (Aldovini and Young, 1990; Dorfman et al., 1993;
Dupraz et al., 1990; Gorelick et al., 1988, 1990; Meric and
Goff, 1989; Meric and Sphar, 1986). Among the earlier
studies, an additional and more subtle role for this struc-
ture in early infection events was suggested by Gorelick
et al. (1988). Recent experiments have confirmed that an
intact CCHC zinc finger structure in the nucleocapsid
protein is strictly required for early infection events in
both HIV-1 and murine leukemia virus (MuLV) (Gorelick
et al., 1993, 1996; Poon et al., 1996; Yu and Darlix, 1996).
These recent findings support use of the nucleocapsid
zinc finger as a therapeutic target since compounds that
can disrupt the zinc finger structure should inactivate
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cell-free virus. This concept has been demonstrated by
several groups who have shown that several hydropho-
bic, mildly oxidizing compounds can destroy the zinc
finger structure by oxidizing the cysteine thiolates that, in
turn, release the coordinated Zn21 ion from the protein.
This electrophilic attack is followed by formation of intra-
and intermolecular disulfide crosslinking between the
cysteines that completely and irreversibly disrupts the
zinc finger in both HIV-1 and MuLV (Chertova et al., 1997;
Rein et al., 1996; Rice et al., 1993, 1995a, 1996; Tummino
et al., 1996). Experiments on cell-free HIV-1 and MuLV
have revealed that some of these compounds can pen-
etrate the viral envelope and react with the nucleocapsid
protein and that these compounds inactivate the virus
(Rein et al., 1996; Rice et al., 1993, 1995a, 1996). Addi-
tionally, treatment of both MuLV- and HIV-1-producing
cells with these compounds inhibits the proper process-
ing of the Gag polyprotein so that these treated cells only
release noninfectious virus (Rein et al., 1996; Turpin et
al., 1996).
Unlike protease and reverse transcriptase inhibitors,
these anti-zinc finger compounds react covalently with
the viral target, NC. Therefore, many biochemical tests
used for enzyme inhibitors that bind only their target
(e.g., calculated KI and Kd) are not pertinent for this type
of anti-retroviral therapy. However, a functional in vivo
test is more likely to discriminate between compounds
that may ultimately work and those that may not. The
ability of these compounds to inhibit HIV-1 in vivo has not
been determined due to the absence of an appropriate
animal model. Given the conservation of the CCHC zinc
finger structure between MuLV and HIV-1, an animal
model that treats Friend MuLV-infected mice with zinc
finger-oxidizing compounds could be used for in vivo
testing of this type of therapy. Mouse models using the
Friend or Rauscher isolates of MuLV, which both induce
an erythroid hyperplasia and splenomegaly in adult mice
using similar mechanisms, have been used to assess
the in vivo effect of several anti-retroviral therapies, in-
cluding AZT (Akarid et al., 1995; Ostertag et al., 1974; Priel
et al., 1993; Ruprecht et al., 1990; Soldaini et al., 1989).
The use of this model is further supported by the essen-
tially parallel results obtained from cell culture testing of
these compounds with MuLV in mouse cells and HIV-1 in
human cells (Rein et al., 1996; Rice et al., 1995a, 1996).
Therefore, any anti-retroviral effects from the Friend
MuLV model are very likely to be effective for HIV-1.
Friend virus is made up of at least two components:
the replication-competent Friend MuLV (F-MuLV) helper
and the defective spleen focus-forming virus (SFFVp)
(Kabat, 1989; Wolff and Ruscetti, 1988). Infection of adult
mice with this virus complex is followed by virus spread
that leads to the infection of a susceptible erythriod
precursor with the SFFVp component of the complex.
This infected cell then undergoes uncontrolled prolifer-
ation, causing Friend disease as manifested by spleno-
megaly and polycytemia. Since the induction of disease
requires viral replication to infect the ‘‘target’’ cells, the
delay or prevention of the development of the disease or
a decrease in the disease symptoms of Friend disease
can be used to assess an inhibition of viral replication.
This mouse system also has the benefits that it is rela-
tively inexpensive and can be done on relatively large
numbers of animals when compared with the primate
models for HIV-1.
We have developed a Friend disease model to deter-
mine if compounds that can react with the zinc finger
demonstrate an anti-retroviral effect in vivo. The results,
using both indirect and direct measures of viral replica-
tion, show that 1 of the 14 compounds tested in this
system was effective at delaying retroviral replication
in vivo.
RESULTS
Effect of compounds on Friend disease using gavage
administration
The development of disease in Friend virus-infected
mice was used as a model to determine whether com-
pounds that attack the NC zinc finger can inhibit retrovi-
ral replication in vivo. This indirect measurement of
MuLV replication is only sensitive to antiviral effects
during the early stage of the disease when disease
development requires replication to infect the suscepti-
ble cells (i.e., the cells that, upon infection, proliferate to
produce the disease) (Kabat, 1989). Therefore, the viral
inoculum to be used with this model needs be kept as
low as possible while maintaining nearly uniform dis-
ease incidence. Experiments with a dilution series of
Friend virus stock disclosed that a viral inoculum of 1 3
103 S1L2 focus-forming units produced uniform inci-
dence with a 29-day median latency. For this model, mice
were treated with compound by gavage twice a week
with a relatively high dose [500 mg/kg body weight (mg/
kg-bwt)] of compound. While many compounds were
well tolerated some compounds showed toxicity (e.g.,
loss of appetite, scruffy coat, lethargy, and occasionally
death). In these cases, the dose given to the mice was
reduced 10-fold (50 mg/kg-bwt) and this lower level of
treatment eliminated the adverse effects. Dosages used
for each compound are presented in Table 1.
Each compound was tested in four groups of mice,
each containing 10 to 15 animals. One control group was
treated with compound but not infected so that any
effects of the treatment alone on the mice would be
detected. Two experimental groups were used to exam-
ine the ability of compound treatment to delay disease
onset: the Pre group commenced treatment 1 week prior
to infection, while the Co group began the gavage treat-
ments coincident with infection. The last group, termed
the Post group, began gavage treatments 2 weeks after
infection. For this group, treatment begins after the viral
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replication stage, when the development of disease de-
pends on the outgrowth of virus-infected cells. Therefore,
this group serves as an important control for the effects
of the compound on this latter, nonviral stage of the
disease that may be mistaken for changes in viral repli-
cation. The median latencies from the Pre- and Co-
treated groups are expressed as percentages of the
control Post-group median latencies (Table 1). Compar-
ing the experimental versus control data in this way
should show the effect of the compounds on viral repli-
cation rather than the effects on Friend disease. A group
of untreated mice was also infected as an additional
control for each trial.
The results from testing 14 compounds that reacted
with HIV-1 NC zinc fingers in vitro are presented in Table
1. Of the compounds tested, Aldrithiol-2 and 2,29-dithio-
bis(benzothialzole) (DTB) appeared to delay the onset of
disease when the median latencies of both Pre and Co
groups were compared to that of the Post control groups.
The median latencies for both Pre and Co groups were
140% of the control Post group for Aldrithiol-2 treatments,
while DTB-treated mice had Pre- and Co-group latencies
that were 150 and 123% of that of the Post group, respec-
tively (Table 1). These results suggest that both of these
compounds may be effective in reducing viral replication
in vivo.
The other compounds did not delay the onset of dis-
ease in both experimental groups. However, some (e.g.,
5,59-dithiobis-(1-phenyl-1H-tetrazole), tetraethythiruam disul-
fide (TED), and tetramethylthiruam disulfide) appeared to
affect only one of the groups, indicating that these com-
pounds might be effective in reducing viral replication
under certain conditions. The remainder of the com-
pounds tested appeared to show little or no effect on
median latency for either the Pre or Co group versus the
Post group, indicating little if any effect on viral replica-
tion (Table 1). Two compounds, 4-iodo-3-nitrobenzamine
and 4-acetamidophenyl disulfide, appeared to produce a
decrease in latency in one of the experimental groups
versus the Post-group control, suggesting that treatment
with these compounds may increase rather than de-
crease viral replication in this model.
Statistical analysis of Aldrithiol-2 and DTB
mouse data
Mouse data from the Aldrithiol-2 and DTB treatments
were analyzed with Kaplan–Meier curves (Kalbfleisch
and Prentice, 1980) and hypotheses regarding differ-
ences between experimental and control groups were
tested with the log rank statistic (Lee, 1992). The result-
ing plots of either the Pre- or Co-treated groups versus
the Post-treated control group for Aldtrithiol-2 and DTB
are shown in Fig. 1. For Aldrithiol-2 (Fig. 1A), the analysis
showed that the Pre-treated group developed disease
with a statistically significant longer latency than the Post
control group (P 5 0.046). However, the comparison
between the Co- and Post-treated groups produced only
marginal support for the hypothesis that this treatment
lengthened the survival of the infected mice (P 5 0.096,
which does meet the confidence criteria of P # 0.05).
These results for Aldrithiol-2 suggest that this compound
TABLE 1
Mice Treated by Gavage Administration
Compound Dosea
Percentage of
Post controlb
Latency of
Post groupcPre Co
Aldrithiol-2 50 140 140 37
2,29-Dithiobis(benzothiazole) (DTB) 500 150 123 25
5,59-Dithiobis-(1-phenyl-1H-tetrazole) 500 100 146 50
Tetraethythiruam disulfide (TED) 500 121 100 29
Tetramethylthiram disulfide 50 97 123 39
2,29-Dithiobis(5-nitropyridine) 500 109 94 35
2,29-Dithiobis(pyridine-N-oxide) 50 108 90 39
2,29-Dithiobis-(4-tertbutyl-1-isopropylimidazole) 500 79 105 38
4,49 Dithiobis(n-(2-hydroxyl-1-napthylmethylene)aniline) 50 92 86 95
Tetraisopropylthiuram disulfide 50 86 81 37
Dithiobis(benzonitrile) 50 85 78 39
Dicyclopentamethylenethiuram disulfide 500 74 91 35
4-Acetamidophenyl disulfide 500 43 96 90
4-Iodo-3-nitrobenzamine 50 5 100 135
a Dose (mg/kg body weight) administered twice a week.
b Latency increase 5 percentage increase in median latency of mice started with compound before infection (Pre) or mice started with compound
at infection (Co) versus mice treated 2 weeks postinfection.
c Median latency of the Post-treated mice in days.
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possesses some in vivo anti-retroviral activity. In con-
trast, the analysis of the DTB groups (Fig. 1B) did not
show a statistically significant difference between the
Pre (P 5 0.19)- or Co-treated (P 5 0.38) groups versus the
Post-treated groups. Thus, while there might be some
anti-viral effect with DTB pretreatment, these tests do not
allow for a significant conclusion to be drawn given the
data.
Direct measurement of viral replication
The gavage study relies on the development of dis-
ease as an indirect measure of viral replication. To di-
rectly measure the effect of zinc finger-oxidizing com-
pounds, mice were exposed to DTB or Aldrithiol-2 in their
feed for 1 week and then infected with Friend virus. Five
mice from each group were sacrificed at specific inter-
FIG. 1. Kaplan–Meier survivor curves of the gavage test data. Graphs of survivors (i.e., mice that have not reached disease endpoint) are presented
comparing either the Pre versus Post or Co versus Post groups for (A) Aldrithiol-2 and (B) DTB. The results of the log rank analysis are indicated on
the figure.
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vals and the number of copies of F-MuLV DNA that are
present in the PBMC of these mice was measured di-
rectly by QC–PCR. This assay was specific for the repli-
cation-competent F-MuLV component of Friend virus
since the PCR primer pair used for amplification was
made to the p15 region of the F-MuLV env and did not
detect either SFFVp sequences or the sequences from
endogenous murine MuLVs (Stoye and Coffin, 1988) that
are present in laboratory strains of mice (data not
shown).
Analysis of the PBMC DNA from mice treated with 500
mg/kg-bwt/day of DTB showed that the treated mice had
levels of F-MuLV DNA that appeared to be somewhat
reduced compared to that of the untreated controls. The
slight difference in virus levels was mostly in the earlier
time points (days 12 and 15), while the levels were
essentially similar at days 19 and 23 (Fig. 2A). These data
suggest that DTB had a very modest effect, if any, on viral
replication.
Aldrithiol-2 was also tested by this method at a daily
dose of 200 mg/kg-bwt/day. The results, presented in Fig.
2B, showed that this compound effectively suppressed
viral replication between days 12 and 19 so that the
amount of viral DNA in the PBMC was below the level of
detection of our PCR assay (less than 1 3 106 copies of
viral DNA in 1 mg of PBMC DNA). However, the amount
of viral DNA in the PBMC increased dramatically in the
day-23 samples to nearly the levels found in the un-
treated controls. Therefore, it appears that while Aldri-
thiol-2 was able to dramatically suppress viral replication
FIG. 2. Summary of the QC–PCR data for the long-term study. Results are presented from the QC–PCR studies for two compounds: (A) DTB and
(B) Aldrithiol-2. Histograms are presented indicating the number of viral copies found in 1 mg of PMBC DNA extracted from each mouse that was
sacrificed for this study. The sampling time points and treatment given to each group are indicated under the graph.
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soon after infection, the virus spreads rapidly between
the 19- and 25-day time points. Taken together, these
results confirm those from the disease model that Aldri-
thiol-2 can reduce viral replication in vivo.
Comparison of Aldrithiol-2, DTB, and TED
The procedure used above was modified so that sev-
eral compounds could be examined at the same time in
a rapid assay by increasing the Friend virus inoculum
10-fold (1 3 104 FFU of F-MuLV as measured by S1L2
assay). This increase allowed for the earlier detection of
the virus in the mouse PBMC. As before, each group of
mice was given ground feed mixed with Aldrithiol-2 (200
mg/kg-bwt/day), DTB (250 mg/kg-bwt/day), TED (500 mg/
kg-bwt/day), or no treatment 1 week before infection and
groups of five mice from each group were sacrificed at 6
and 12 days postinfection. DNAs extracted from the
PBMC of each mouse were analyzed by QC–PCR to
determine the amount of provirus present in these cells.
The results for the 6-day samples (Fig. 3A) demonstrated
that PBMC DNA from four of five mice treated with DTB
had detectable levels of viral DNA, but these levels
appeared to be somewhat lower than that of the control
group (Fig. 3A). In contrast, none of the mice treated with
Aldrithiol-2 had detectable levels of F-MuLV DNA, less
than 1 3 106 copies/mg DNA, indicating that this treat-
ment dramatically suppressed viral replication. Interest-
ingly, four of five mice treated with TED contained levels
of viral DNA that appeared to be considerably higher
than those of the other groups (Fig. 3A), suggesting that
TED treatment may initially increase viral replication.
Consistent with this possibility, other experiments using
a Friend disease model also suggest that TED de-
creased latency (i.e., accelerated disease induction)
(data not shown).
The results from the mice sacrificed at day 12 (Fig. 3B)
showed that the levels of viral DNA in the PBMC from
most of the groups of mice studied had increased over
the 6-day time point. Of the four groups, the levels of
provirus in the Aldrithiol-2-treated mice at 12 days had
increased the most, rising dramatically higher than the
day-6 levels and being detected at levels near that of the
control group (Fig. 3B). These results are similar to those
found in the longer term study for Aldrithiol-2 presented
in Fig. 2B, which also showed a rapid increase in virus
levels at the latter time points. This sudden increase in
F-MuLV DNA at the latter time points is most likely to be
due to viral replication. However, an alternative explana-
tion for these data is that an outgrowth of hyperplastic
cells infected by both SFFVp and F-MuLV (a step in
Friend disease) is the cause of the increase in F-MuLV
DNA in the PBMC. This is unlikely to be the case be-
cause the spleens for these animals were not signifi-
cantly larger (;0.1 g) than those for uninfected mice,
indicating an absence of large numbers of diseased
cells (data not shown). Additionally, the DNAs from the
12-day samples, which contain high levels of F-MuLV
[nearly 1 3 1010 copies/mg PMBC DNA (Fig. 3B)] did not
contain detectable levels of SFFVp DNA, as measured by
a QC–PCR assay (data not shown), which would be
present in the rapidly proliferating cells. These two ob-
servations indicate that the increase in F-MuLV DNA
detected between the 6- and 12-day time points is due to
viral spread rather than an increase in provirus-contain-
ing hyperplasic cells induced by a SFFVp infection.
The DTB-treated mice at the 12-day time point also
showed an increase in the levels of viral DNA over the
6-day samples, with viral levels equaling those of the
untreated group (Fig. 3B). These data essentially
agree with the longer term study presented in Fig. 2A.
The animals treated with TED had levels of virus that
were somewhat lower at day 12 than the 6-day sam-
ples and were similar to those of untreated mice at day
12 (Fig. 3B).
DISCUSSION
The data presented above are the first demonstration
that a compound which reacts with the CCHC structure
of NC can inhibit retroviral replication in vivo. Using
murine Friend disease to indirectly and directly measure
MuLV replication in mice, administration of Aldrithiol-2 (a
hydrophobic disulfide compound) was found to suppress
viral replication. The indirect study measured the ability
of a compound to delay the appearance of Friend dis-
ease in infected mice. Of the 14 compounds tested by
gavage, only Aldrithiol-2 significantly delayed the onset
of disease (and subsequent survival) as measured by
Kaplan–Meier curves and log rank statistic analyses.
Direct detection of viral DNA in the PBMC of infected
mice using QC–PCR showed that treatment with Aldri-
thiol-2 suppressed viral replication, confirming the con-
clusions based on the disease data.
While Aldrithiol-2 inhibited the spread of F-MuLV
shortly after infection (levels of virus were held below our
level of detection), treatment with compound ultimately
failed to eliminate replication in the long term. Two pos-
sible mechanisms for the increase in virus levels despite
Aldrithiol-2 treatment are the development of viral resis-
tance to the compound, as occurs with other anti-retro-
viral therapies, or an accelerated metabolic breakdown
of the compound within the mouse (induced by exposure
to large doses of this mildly oxidizing compound). Of the
two possibilities, a viral mutant to Aldrithiol-2 appears to
be unlikely, as there is an absolute requirement for the
CCHC zinc-coordinating structure that is attacked by the
compound (Gorelick et al., 1993, 1996; Poon et al., 1996;
Yu and Darlix, 1996). Additionally, a previous study with
HIV-1 in a tissue culture system using similar zinc finger-
oxidizing compounds failed to produce resistant viruses
under conditions that have produced escape mutants for
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both reverse transcriptase and protease inhibitors (Rice
et al., 1995a). While the reason Aldrithiol-2 is not able to
suppress viral replication in the long term is unclear, it is
likely that the compound is being increasingly eliminated
from the mouse as treatment progresses, causing the
increase in virus replication. Experiments are currently in
progress to test both viral mutant and increased metab-
olism possibilities.
The remaining 13 compounds showed little, if any,
significant activity despite being found effective in either
biochemical or tissue culture assays. DTB, while appear-
ing to be effective when just median latencies were
compared, was not significantly different from the control
group in the gavage test as analyzed by Kaplan–Meier
curves and log rank statistic analyses. Additionally, the
QC–PCR data showed only weak suppression of the
virus in the DTB-treated mice. While these compounds
appeared to be effective in biochemical and cell culture
FIG. 3. Summary of the 6- and 12-day tests measured by QC–PCR. Results are presented from the QC–PCR studies for Aldrithiol, DTB, and TED
sampled at two time points: (A) 6 days postinfection and (B) 12 days postinfection. Histograms are presented indicating the viral copies found in 1
mg PMBC DNA of each mouse. The respective treatments for each mouse are indicated under the graph.
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assays, it is likely that these compounds act and react
differently within an organism than in those simpler sys-
tems. Possible factors that could render these com-
pounds inactive in vivo are metabolic degradation, de-
pletion of the compound by reactions with nonviral pro-
teins, or sequestration in a compartment (e.g., in fatty
tissue) that keeps it from interacting with virus. Our data
suggest that the potential reactions which these com-
pounds can undergo in vivo are not yet adequately mod-
eled by in vitro assays and underscore the importance of
testing potential anti-retroviral compounds with an in vivo
model.
An interpretation of these negative results is also
complicated by the potential of these compounds to
modulate the oxidation-reduction balance in the
mouse. Recently Palamara et al. (1996) reported that
injections of reduced glutathione decreased viral rep-
lication as measured by a MAIDS disease model.
These results may suggest that increasing the reduc-
ing atmosphere in the mouse might reduce viral rep-
lication. It is interesting to note that our QC–PCR data
demonstrated that TED increased rather than de-
creased viral replication (Fig. 3A). Given the results of
Palmara et al., it is possible that this increase in viral
replication may be due to an increased oxidative state
in the mouse, caused by the ingestion of TED, that
could mask a weak antiviral effect of this compound. It
is interesting to note that two other compounds, 4-ac-
etamidophenyl disulfide and 4-iodo-3-nitrobenzamine,
also appeared to accelerate the disease onset and,
presumably, viral replication.
The exposure of tissue culture cells to some of these
compounds has produced toxic effects in vitro (Rein et
al., 1996). However, these types of compounds are rela-
tively nontoxic in vivo: DTB and TED have rodent LD50
values of 7.8 and 8.6 g/kg body, respectively (Budavari,
1989). (The LD50 of Aldrithiol-2 has not been published.)
Our experiments with these compounds agree with
these toxicity studies: all of these compounds were
readily tolerated at 50 mg/kg-bdwt, with many tolerated
at 500 mg/kg-bdwt. These data clearly show that a com-
pound which attacks the nucleocapsid zinc finger can
inhibit retroviral replication in vivo without acute toxicity.
Since the cytoplasm of the cell is a reducing environ-
ment, it is likely that these mild oxidants are promptly
reduced upon entering the cell, as proposed by Rein et
al. (1996).
Even though zinc finger proteins are essential parts of
vital cellular proteins, the retroviral NC zinc finger
(CCHC) is structurally different from the two other zinc
finger prototypes (CCHH and CCCC) predominantly
found in mammalian proteins (Berg and Shi, 1996).
Therefore, these chemical differences may be able to be
used to design effective antiviral compounds to specifi-
cally attack the retroviral nucleocapsid zinc finger. Also,
since the ultimate virus-inactivating compound could
possibly be a metabolic derivative of the compound orig-
inally administered, it is also important to examine the
metabolic fate of these compounds in vivo. The in vivo
model presented here could be used as an inexpensive
test to evaluate other zinc finger-reacting compounds for
anti-retroviral viral effect.
From our results, the nucleocapsid protein appears to
be a promising target for the development of anti-retro-
viral drugs. Since the CCHC structure is strictly con-
served among all oncoviruses and lentiviruses, the com-
pounds that are effective against MuLV are likely to be
effective against HIV and other pathogenic retroviruses.
However, this should be directly tested using an in vivo
AIDS model (e.g., SCID-Hu mouse and SIV/macaque) for
each candidate compound.
MATERIAL AND METHODS
Mice
Four- to six-week-old NIH/Swiss mice (Animal Produc-
tion Facility, National Cancer Institute-Frederick Re-
search and Development Center, Frederick, MD) were
infected by injection of 0.1 ml of Friend virus (polycytemic
strain) produced from the 3-6 A/F-MuLV cell line, an
NIH3T3 cell line that produces a mixture Friend MuLV
(F-MuLV) and SFFVp (a gift of Sandra Ruscetti, Laboratory
of Molecular Oncogenesis, National Cancer Institute-
Frederick Research and Development Center, Frederick,
MD). Viral stocks were titered for the presence of the
Friend murine leukemia virus (F-MuLV) by the S1L2
focus assay (Bassin et al., 1971). Compounds used for
this study were administered either by gavage with a
finely ground powder suspended in vegetable oil twice a
week or as a pulverized powder mixed with ground
mouse feed. The feed treatments assumed 4 g of feed
eaten per mouse and this rate of consumption was
verified by measuring the amount of food dispensed. For
the disease model, mice were observed for disease by
visual examination and palpation. Those animals judged
to have enlarged spleens (greater than 1 g) were bled for
a heparinized blood sample before the spleen was col-
lected.
Polymerase chain reaction analysis
Peripheral blood mononuclear cells (PBMC) were iso-
lated from the mouse blood samples by centrifugation
through a PBS solution onto a Ficoll–Paque cushion at
2000 g in a Sorvall JS-4.2 rotor at 4°C for 5 min. DNAs
were harvested from cells by a proteinase K/phenol
chloroform procedure as previously described (Ott et al.,
1995). DNAs were quantitated by A260 and 1 mg of high-
molecular-weight genomic DNA was analyzed by poly-
merase chain reaction (PCR) using the AmpliTaq DNA
polymerase kit (Perkin–Elmer, Branchburg, NJ) according
to the manufacturer’s instructions using the suggested 2
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mM MgCl2 concentration and an amplification program
of a cycle, 94°C for 10 s, 63°C for 10 s, and 72°C for 30 s,
repeated 40 times followed by a hold, 72°C for 8 min, and
ended with an indefinite 4°C hold. All amplifications
were done with the Perkin–Elmer Geneamp PCR System
9600 thermocycler. Sense primers used for the amplifi-
cations were either F-MuLV-specific FMuLV5003S: TGT-
TCCTAAAAGAAGGAGGACTGTGT, which corresponds to
nucleotides 2384 to 2409 (according to the sequence of
Koch et al., 1983), or SFFVp-specific SFFV5015S: TAAT-
TCTAATCATACCTCTGCCCTAAAA, which corresponds to
nucleotides 5015 to 5042 (according to Amanuma et al.
(1983). A common antisense primer was used with both
sense primers: SFFV5458AS (TATCGTGGCTCGTATTCT-
AGTGGTT), which is complimentary to F-MuLV nucleo-
tides 2744 to 2720 and SFFVp nucleotides 5372 to 5348
and produces products of 361 and 358 nucleotides dur-
ing PCR amplification of the respective virus sequences.
For quantitative competitive PCR, a competitor sequence
was produced by amplification of the viral molecular
clones using the respective sense primers and another
antisense primer: SFFV5277AS (TATCGTGGCTCGTATT-
CTAGTGGTTAACCGATTAAGAATGCAGGGTCCA) that hy-
bridizes to a sequence 70 bp upstream (starting at anti-
sense nucleotides 2649 in the F-MuLV and 5277 in the
SFFVp sequences) from the common antisense primer
(SFFV5458AS) that was used for the PCR detection. In
addition to this upstream sequence, the SFFV5458AS
sequence was added to the 59 end of this primer (indi-
cated by underlining). Amplification using this primer on
either the F-MuLV or the SFFV plasmids with the respec-
tive sense primer, F-MuLV 5003S or SFFV5015S, pro-
duces a product of either F-MuLV or SFFV sequences
which contain a 70-bp internal deletion that is appropri-
ate to use as a competitor sequence for QC–PCR since
it has the SFFV5458AS sequence on its 39 end. The
resultant products were cloned into the EcoRV site of
pZero (Invitrogen Corporation, Carlsbad, CA) and these
plasmids were used as competitor DNAs in QC–PCR
assays according to the method of Piatak et al. (1993).
PCR products were electrophoresed through 1.8% Meta-
phor agarose gels (FMC Corp., Rockland, ME) run with
TBE buffer (45 mM tris, 45 mM borate, 2 mM EDTA) and
visualized by fluorescence after ethidium bromide stain-
ing, which readily distinguished the competitor from the
full-length product.
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